Haemonetics (NYSE: HAE) reported Q4 EPS of $0.69, $0.04 worse than the analyst estimate of $0.73. Revenue for the quarter came in at $238 million versus the consensus estimate of $247.15 million.

FISCAL 2021 GUIDANCE:

Given the uncertainty around the full impact and duration of the COVID-19 pandemic, and the nature and timing of the associated economic recovery, Haemonetics is not issuing annual guidance at this time. The Company is currently assessing potential scenarios for the macroeconomic impact of COVID-19 and the related effect on healthcare beyond the current quarter, informed by milestones and market indicators that unfold over the coming weeks. As a result the Company intends to issue guidance later in its fiscal year.

For earnings history and earnings-related data on Haemonetics (HAE) click here.